mark levis, md, phd, discusses what we've learned about gilteritinib in flt3 mutated aml patients
Published 6 years ago • 147 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
2:28
dr. levis on gilteritinib in relapsed/refractory flt3-mutated aml
-
2:03
mark levis, md, phd, on factors influencing 1st line therapy in aml patients with flt3 mutations
-
1:08
mark levis, md discusses importance of hitting the flt3 target in aml patients with this mutation
-
1:50
mark levis, md, on why the flt3 target is important in aml
-
6:03
mark j. levis, md, phd
-
1:52
mark levis, md, phd, speculates on evolving treatment considerations for flt3 mutated aml
-
2:45
acute myeloid leukemia aml animation
-
57:49
acute myeloid leukemia with myelodysplasia-related changes (aml-mrc): - j. f. zeidner - 20221116
-
18:58
naval daver - flt3 mutations in aml
-
1:50
mechanisms of gilteritinib resistance in flt3-mutated aml
-
1:58
unanswered questions that remain in flt3-mutated aml
-
1:33
is gilteritinib the new breakthrough in the treatment of flt3-mutated aml?
-
6:18
previously untreated flt3-mutated aml
-
1:18
dr. levis discusses the ideal use of quizartinib in flt3-itd aml
-
1:04
dr. levis on quizartinib in aml patients without the flt3-itd mutation
-
1:20
mark levis, md, phd, comments on measurable residual disease in relapsed/refractory aml
-
3:01
admiral: gilteritinib for r/r flt3-mutated aml
-
2:12
mrd and cr impact survival in gilteritinib-treated flt3 r/r aml
-
0:37
mark levis, md, comments on attributes of crenolanib in relapsed flt3 positive aml
-
1:26
eunice wang, md, shares what we've learned about gilteritinib since the 2017 asco annual meeting
-
1:08
mark levis, md comments on the importance of hitting multiple flt3 components such as itd and d-835
-
4:10
final thoughts on emerging therapies for aml